Cargando…

Oral Mucositis Induced By Anticancer Therapies

Oral mucositis induced by conventional cytotoxic cancer therapies is a common and significant clinical problem in oncology. Mucositis symptoms, which include severe pain, may lead to dose reductions and unplanned interruptions of chemotherapy and/or radiotherapy, and often affect patients' qual...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Ansari, Sali, Zecha, Judith A. E. M., Barasch, Andrei, de Lange, Jan, Rozema, Fred R., Raber-Durlacher, Judith E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623065/
https://www.ncbi.nlm.nih.gov/pubmed/26523246
http://dx.doi.org/10.1007/s40496-015-0069-4
_version_ 1782397635371466752
author Al-Ansari, Sali
Zecha, Judith A. E. M.
Barasch, Andrei
de Lange, Jan
Rozema, Fred R.
Raber-Durlacher, Judith E.
author_facet Al-Ansari, Sali
Zecha, Judith A. E. M.
Barasch, Andrei
de Lange, Jan
Rozema, Fred R.
Raber-Durlacher, Judith E.
author_sort Al-Ansari, Sali
collection PubMed
description Oral mucositis induced by conventional cytotoxic cancer therapies is a common and significant clinical problem in oncology. Mucositis symptoms, which include severe pain, may lead to dose reductions and unplanned interruptions of chemotherapy and/or radiotherapy, and often affect patients' quality of life. In addition, ulcerative mucositis represents a risk factor for local or systemic infectious complications that may be life-threatening in immunosuppressed patients. The development of biologically based targeted cancer therapies, which aim to block the growth, spread, and survival of tumors by interfering with specific molecular targets, may have reduced mucosal injury, but did not eliminate it. This article will review the epidemiology, pathobiology, and management of oral mucositis associated with conventional cytotoxic therapies for malignant diseases and will briefly summarize emerging information on oral mucosal injury associated with targeted therapies. Considerations for future research aimed at the development of more efficient and effective supportive care approaches will be presented, with emphasis on the contribution of dental researchers and clinicians in these efforts.
format Online
Article
Text
id pubmed-4623065
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-46230652015-10-30 Oral Mucositis Induced By Anticancer Therapies Al-Ansari, Sali Zecha, Judith A. E. M. Barasch, Andrei de Lange, Jan Rozema, Fred R. Raber-Durlacher, Judith E. Curr Oral Health Rep Epidemiology (M Laine, Section Editor) Oral mucositis induced by conventional cytotoxic cancer therapies is a common and significant clinical problem in oncology. Mucositis symptoms, which include severe pain, may lead to dose reductions and unplanned interruptions of chemotherapy and/or radiotherapy, and often affect patients' quality of life. In addition, ulcerative mucositis represents a risk factor for local or systemic infectious complications that may be life-threatening in immunosuppressed patients. The development of biologically based targeted cancer therapies, which aim to block the growth, spread, and survival of tumors by interfering with specific molecular targets, may have reduced mucosal injury, but did not eliminate it. This article will review the epidemiology, pathobiology, and management of oral mucositis associated with conventional cytotoxic therapies for malignant diseases and will briefly summarize emerging information on oral mucosal injury associated with targeted therapies. Considerations for future research aimed at the development of more efficient and effective supportive care approaches will be presented, with emphasis on the contribution of dental researchers and clinicians in these efforts. Springer International Publishing 2015-10-19 2015 /pmc/articles/PMC4623065/ /pubmed/26523246 http://dx.doi.org/10.1007/s40496-015-0069-4 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Epidemiology (M Laine, Section Editor)
Al-Ansari, Sali
Zecha, Judith A. E. M.
Barasch, Andrei
de Lange, Jan
Rozema, Fred R.
Raber-Durlacher, Judith E.
Oral Mucositis Induced By Anticancer Therapies
title Oral Mucositis Induced By Anticancer Therapies
title_full Oral Mucositis Induced By Anticancer Therapies
title_fullStr Oral Mucositis Induced By Anticancer Therapies
title_full_unstemmed Oral Mucositis Induced By Anticancer Therapies
title_short Oral Mucositis Induced By Anticancer Therapies
title_sort oral mucositis induced by anticancer therapies
topic Epidemiology (M Laine, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623065/
https://www.ncbi.nlm.nih.gov/pubmed/26523246
http://dx.doi.org/10.1007/s40496-015-0069-4
work_keys_str_mv AT alansarisali oralmucositisinducedbyanticancertherapies
AT zechajudithaem oralmucositisinducedbyanticancertherapies
AT baraschandrei oralmucositisinducedbyanticancertherapies
AT delangejan oralmucositisinducedbyanticancertherapies
AT rozemafredr oralmucositisinducedbyanticancertherapies
AT raberdurlacherjudithe oralmucositisinducedbyanticancertherapies